B7 family checkpoint regulators in immune regulation and disease

Trends in Immunology

Volumn 34, Issue 11, 2013, Pages 556-563

  Ceeraz, Sabrina ^a   Nowak, Elizabeth C ^a   Noelle, Randolph J ^a,b  

^a NORRIS COTTON CANCER CENTER   (United States)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

B7 family; Co inhibitory molecules; Co stimulatory molecules

Indexed keywords

ADENOSINE PHOSPHATE; AMP 224; B AND T LYMPHOCYTE ATTENUATOR; B7 ANTIGEN; BELATACEPT; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GP 100 PEPTIDE VACCINE; HERPESVIRUS ENTRY MEDIATOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; IPILIMUMAB; LYMPHOCYTE ANTIGEN; MDX 1105; MINOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NIVOLUMAB; PEPTIDE VACCINE; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 LIGAND 2 MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN B7 H3; PROTEIN B7 H6; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; V SET DOMAIN IMMUNOGLOBULIN SUPPRESSOR OF T CELL ACTIVATION;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER PATIENT; CANCER SURVIVAL; DENDRITIC CELL; DRUG HALF LIFE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GLIOMA; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE;

B7 FAMILY; CO-INHIBITORY MOLECULES; CO-STIMULATORY MOLECULES;

ANIMALS; B7 ANTIGENS; CTLA-4 ANTIGEN; HUMANS; IMMUNE TOLERANCE; IMMUNITY; PROGRAMMED CELL DEATH 1 RECEPTOR; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84886948036     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.07.003     Document Type: Review

References (114)

1. Jenkins M.K. The ups and downs of T cell costimulation. Immunity 1994, 1:443-446.
2. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
3. Green J.M., et al. T cell costimulation through the CD28 receptor. Proc. Assoc. Am. Phys. 1995, 107:41-46.
4. Greenfield E.A., et al. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 1998, 18:389-418.
5. Viola A., Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996, 273:104-106.
6. Boise L.H., et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995, 3:87-98.
7. Rulifson I.C., et al. CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 1997, 158:658-665.
8. Tang Q., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 2003, 171:3348-3352.
9. Suntharalingam G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
10. Eastwood D., et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 2010, 161:512-526.
11. Romer P.S., et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011, 118:6772-6782.
12. Waibler Z., et al. Toward experimental assessment of receptor occupancy: TGN1412 revisited. J. Allergy Clin. Immunol. 2008, 122:890-892.
13. Swallow M.M., et al. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999, 11:423-432.
14. Yoshinaga S.K., et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999, 402:827-832.
15. Yao S., et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011, 34:729-740.
16. Choi Y.S., et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011, 34:932-946.
17. Hutloff A., et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
18. McAdam A.J., et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J. Immunol. 2000, 165:5035-5040.
19. Coyle A.J., et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000, 13:95-105.
20. Park H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
21. Dong C., et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001, 409:97-101.
22. Dong C., Nurieva R.I. Regulation of immune and autoimmune responses by ICOS. J. Autoimmun. 2003, 21:255-260.
23. Prevot N., et al. Abrogation of ICOS/ICOS ligand costimulation in NOD mice results in autoimmune deviation toward the neuromuscular system. Eur. J. Immunol. 2010, 40:2267-2276.
24. Fu T., et al. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011, 71:5445-5454.
25. Walunas T.L., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
26. Salama A.K., Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 2011, 17:4622-4628.
27. Qureshi O.S., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
28. Waterhouse P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
29. Cross A.H., et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 1995, 95:2783-2789.
30. Knoerzer D.B., et al. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin. Invest. 1995, 96:987-993.
31. Finck B.K., et al. Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
32. Cutolo M., Nadler S.G. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun. Rev. 2013, 12:758-767.
33. Alvarez-Quiroga C., et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J. Clin. Immunol. 2011, 31:588-595.
34. Viglietta V., et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008, 71:917-924.
35. Orban T., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
36. Furuzawa-Carballeda J., et al. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant. Proc. 2010, 42:3489-3496.
37. Pardoll D., Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med. 2012, 209:201-209.
38. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol. 2010, 37:450-454.
39. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
40. Liakou C.I., et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14987-14992.
41. Yuan J., et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16723-16728.
42. Small E.J., et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2007, 13:1810-1815.
43. He Y.F., et al. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J. Immunol. 2004, 173:4919-4928.
44. Parry R.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005, 25:9543-9553.
45. Butte M.J., et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
46. Nishimura H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
47. Nishimura H., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
48. Ansari M.J., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 2003, 198:63-69.
49. Salama A.D., et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 2003, 198:71-78.
50. Wang W., et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int. Immunol. 2009, 21:1065-1077.
51. Berger R., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14:3044-3051.
52. Brahmer J.R., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
53. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
54. Watanabe N., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 2003, 4:670-679.
55. Steinberg M.W., et al. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 2011, 244:169-187.
56. Compaan D.M., et al. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J. Biol. Chem. 2005, 280:39553-39561.
57. Oya Y., et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum. 2008, 58:2498-2510.
58. Tao R., et al. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J. Immunol. 2005, 175:5774-5782.
59. Hobo W., et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J. Immunol. 2012, 189:39-49.
60. Chapoval A.I., et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2001, 2:269-274.
61. Sun M., et al. Characterization of mouse and human B7-H3 genes. J. Immunol. 2002, 168:6294-6297.
62. Zhang G., et al. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 2008, 123:538-546.
63. Chen X., et al. Circulating B7-H3(CD276) elevations in cerebrospinal fluid and plasma of children with bacterial meningitis. J. Mol. Neurosci. 2009, 37:86-94.
64. Zhang G., et al. B7-H3 augments the inflammatory response and is associated with human sepsis. J. Immunol. 2010, 185:3677-3684.
65. Hashiguchi M., et al. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10495-10500.
66. Leitner J., et al. B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur. J. Immunol. 2009, 39:1754-1764.
67. Xu H., et al. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009, 69:6275-6281.
68. Kramer K., et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J. Neurooncol. 2010, 97:409-418.
69. Zhou Z., et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J. Neurooncol. 2012, 111:257-264.
70. Arigami T., et al. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci. 2011, 102:1019-1024.
71. Yuan H., et al. B7-H3 over expression in prostate cancer promotes tumor cell progression. J. Urol. 2011, 186:1093-1099.
72. Chavin G., et al. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin. Cancer Res. 2009, 15:2174-2180.
73. Arigami T., et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg. 2010, 252:1044-1051.
74. Zhang G., et al. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer 2009, 66:245-249.
75. Brunner A., et al. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol. Oncol. 2011, 124:105-111.
76. Tekle C., et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int. J. Cancer 2012, 130:2282-2290.
77. Sun J., et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol. Immunother. 2010, 59:1163-1171.
78. Chen C., et al. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp. Cell Res. 2012, 319:96-102.
79. Katayama A., et al. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. Int. J. Oncol. 2011, 38:1219-1226.
80. Prasad D.V., et al. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003, 18:863-873.
81. Choi I.H., et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 2003, 171:4650-4654.
82. Sica G.L., et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003, 18:849-861.
83. Zang X., et al. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10388-10392.
84. Kamimura Y., et al. Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses. Biochem. Biophys. Res. Commun. 2009, 389:349-353.
85. Wang X., et al. B7-H4 Treatment of T cells inhibits ERK, JNK, p38, and AKT activation. PLoS ONE 2012, 7:e28232.
86. Zhu G., et al. B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 2009, 113:1759-1767.
87. Lee J.S., et al. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J. Immunol. 2012, 189:4165-4174.
88. Wei J., et al. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J. Exp. Med. 2011, 208:1683-1694.
89. Wang X., et al. Endogenous expression of B7-H4 improves long-term murine islet allograft survival. Transplantation 2013, 95:94-99.
90. Wang X., et al. B7-H4 induces donor-specific tolerance in mouse islet allografts. Cell Transplant. 2012, 21:99-111.
91. Wang X., et al. Local expression of B7-H4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival. Transplantation 2009, 87:482-490.
92. Yuan C.L., et al. B7-H4 transfection prolongs beta-cell graft survival. Transpl. Immunol. 2009, 21:143-149.
93. Wang X., et al. Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes 2011, 60:3246-3255.
94. Azuma T., et al. Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med. 2009, 6:e1000166.
95. Arigami T., et al. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J. Surg. 2011, 35:2051-2057.
96. Arigami T., et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J. Surg. Oncol. 2010, 102:748-752.
97. Jiang J., et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 2010, 59:1707-1714.
98. Sun S.Q., et al. Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines. J. Int. Med. Res. 2012, 40:497-506.
99. Chen C., et al. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett. 2012, 317:99-105.
100. Chen C., et al. Increase of circulating B7-H4-expressing CD68+ macrophage correlated with clinical stage of lung carcinomas. J. Immunother. 2012, 35:354-358.
101. Chen L.J., et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 2011, 60:1047-1055.
102. Quandt D., et al. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 2011, 17:3100-3111.
103. Cheng L., et al. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int. J. Gynecol. Cancer 2009, 19:1481-1486.
104. Yao Y., et al. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J. Neurooncol. 2008, 89:121-129.
105. Song H., et al. B7-H4 reverse signaling induces the apoptosis of EBV-transformed B cells through Fas ligand up-regulation. Cancer Lett. 2008, 266:227-237.
106. Park G.B., et al. Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology 2009, 128:360-368.
107. Brandt C.S., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 2009, 206:1495-1503.
108. Li Y., et al. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J. Exp. Med. 2011, 208:703-714.
109. Kellner C., et al. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J. Immunol. 2012, 189:5037-5046.
110. Zhang T., et al. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J. Immunol. 2012, 189:2290-2299.
111. Wang L., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011, 208:577-592.
112. Aloia L., et al. Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells. J. Biol. Chem. 2010, 285:7776-7783.
113. Sakr M.A., et al. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci. 2010, 101:2368-2374.
114. Flies D.B., et al. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 2011, 187:1537-1541.